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(HNPCC)Summary Colorectal cancer (CRC) is a neoplastic disease in which normal mucosa undergoes a process of
malignant transformation due to the progressive accumulation of molecular alterations affecting proto-
oncogenes and oncosuppressor genes. Some of thesemodifications exert their carcinogenic potential by pro-
moting a constitutive activation of the β-catenin signaling proliferation pathway, and when present, loss of
cadherin expression also significantly contributes to the same effect. Using a combined approach of molec-
ular and immunohistochemical analysis, we have previously demonstrated that most sporadic CRCs exhibit
a down-regulated expression of a cadherin, named μ-protocadherin, that is generally observed in association
with a higher proliferation rate and a worse prognosis. The aim of this report was to perform a comparative
immunohistochemical assessment of μ-protocadherin and a similar cadherin, named protocadherin-24, in
sporadic CRC and hereditary nonpolyposis colorectal cancer. The data obtained put in evidence that dou-
ble-negative CRCs, lacking both the analyzed protocadherins, are more represented among sporadic tumors,
whereas double-positive CRCs, maintaining their expression, exhibit an opposite trend. As expected, loss of
protocadherin expression was accompanied by nuclear localization of β-catenin and increased positivity of
the Ki-67 proliferation marker. This finding is consistent with the different clinical evolution of the 2 con-
sidered CRC sets according to which patients with hereditary nonpolyposis colorectal cancer experience a
better prognosis as compared with those affected by a sporadic CRC.
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Colorectal cancer (CRC) is a neoplastic condition of great
medical and social interest, and despite the considerable prog-
ress achieved in the comprehension of its molecular pathogen-
esis, it remains the most frequent tumor in general population
and the second cause of cancer-related death in Western coun-
tries [1]. The development of CRC is a multistep process in
which a series of genetic and epigenetic alterations activates
proto-oncogenes and inactivates oncosuppressor genes, lead-
ing to the malignant transformation of colorectal mucosa cells
[2,3]. The initial, and probably most important, among such
modifications determines a constitutive activation of the β-
catenin signaling pathway, resulting in an increased prolifera-
tion of CRC cells. Although mutations inactivating the APC
oncosuppressor gene represent the main factor responsible
for β-catenin activation, a growing body of evidence suggests
that loss of cadherin expression, believed to occur as a conse-
quence of epigenetic events, significantly contributes to the
same effect, playing also an important role in the acquisition
of an invasive phenotype [4,5]. In this regard, the assessment
of E-cadherin involvement has led to controversial results in
the past, indicating that, at best, the expression of this cadherin
is lost in a limited number of CRCs. On the contrary, data ob-
tained in our laboratory using a combined approach of micro-
array meta-analysis and immunohistochemical evaluation
allowed us to demonstrate that most CRCs undergo a down-
regulated expression of a distinct cadherin, namely μ-
protocadherin, that was observed together with higher levels
of the Ki-67 proliferation marker and a reduced probability
to achieve a 5-year disease-free survival [6,7]. Functional stud-
ies, carried out to better characterize the biological role of this
adhesion molecule, put in evidence that, as observed for other
cadherins, the oncosuppressive property of μ-protocadherin is
due to the capacity to sequester β-catenin in a submembrane
location, inhibiting its nuclear translocation and the subse-
quent proliferation effect mediated by the transcription of its
target genes [8,9]. Consistently with these findings, treatment
of CRC cells with pharmacological inhibitors of the β-catenin
pathway, such as mesalazine (5-ASA) or FH535, strongly up-
regulates μ-protocadherin expression disclosing an involve-
ment of this cadherin in the response to drugs that are poten-
tially endowed with an anti-CRC chemoprevention activity
[10]. It is interesting to consider that a couple of reports pub-
lished some years ago suggested the existence of a similar cad-
herin, called protocadherin-24, that shares some of the
biological properties already ascribed to μ-protocadherin in-
cluding its particular expression pattern (restricted to the liver,
kidney, and colon) and its capacity to inhibit β-catenin
[11,12]. Based on this premise, the aim of our article was to
better characterize the similarity of μ-protocadherin with
protocadherin-24 and to perform an immunohistochemical
survey to assess their expression in 2 separate sets of sporadic
CRCs and hereditary nonpolyposis colorectal cancers
(HNPCCs). The results obtained confirmed the relationship
between μ-protocadherin and protocadherin-24, indicatingthat double-negative samples (lacking the expression of both
protocadherins) prevail among sporadic CRCs, whereas dou-
ble-positive tumors (maintaining the expression of both proto-
cadherins) are more represented in HNPCC. Notably, this
particular expression pattern is in perfect agreement with the
different clinical outcomes of the 2 considered groups of ma-
lignancies according to which HNPCC tumors experience a
better prognosis as compared with sporadic CRCs.2. Materials and methods
2.1. Patients identification
A group of 70 patients with sporadic CRC was identified
through the archive of Unit of Pathology of Modena. The tu-
mor samples were taken by patients undergoing colorectal sur-
gical resection. The work was carried out in agreement with
the Declaration of Helsinki, obtaining the informed consent
from patients. All histologic preparations were examined by
the pathologist (L. L.) by selecting the block containing both
the neoplasia and the normal mucosa to be used as an internal
control. The tumor stage was determined according to the
TNM classification of the American Joint Committee on
Cancer [13]. Forty-one male and 29 female patients with 7 car-
cinomas in stage I, 26 in stage II, 24 in stage III, and 13 in stage
IV were studied. The onset age ranged from 42 to 88 years,
with an average age of 65 years. The neoplasia was localized
to the right colon in 16 cases, in 32 to the left colon, and 22
to the rectum. Recurrences and metastasis after surgery were
established by the investigation of clinical files and pathologi-
cal reports of patients.
In addition, 15 cases of hereditary colorectal carcinoma
(HNPCC or Lynch syndrome), previously studied and with
mutations known in the genes of mismatch repair [14-16],
were analyzed, with 10 male and 5 female patients, of which
3 carcinomas in stage I, 7 in stage II, and 5 in stage III. The on-
set ages ranged from 19 to 75 years, with an average age of 47
years. The neoplasia was localized to the right colon in 9 cases
and 6 to the left colon. The germ-line mutations were 7 in the
MLH1, 6 gene in the MSH2 gene, and 2 in the MSH6 gene.
2.2. Immunohistochemical analysis
For each case, a representative paraffin-embedded block
containing tumor tissue and normal mucosa was sectioned at 4
μm. Immunoperoxidase staining was run with the Benchmark
XT Automatic Staining System using diaminobenzidine as
chromogen (Roche,Monza, Italy) and using theViewDABDe-
tection Kit (Roche). At the end of the reaction, slides were coun-
terstained with hematoxylin. Mouse monoclonal antibodies
antihuman β-catenin (Roche), anti-MLH1 (Roche), and antihu-
man E-cadherin (clone NCH-38; Dako, Glostrup, Denmark)
were used using prediluted commercially available prepara-
tions. Mouse monoclonal antihuman Ki-67 antibody (MIB-1;
Fig. 1 A, Microarray analysis of protocadherin-24 mRNA expression performed in 2 publicly available CRC data sets (right and left). Results
are presented as bar histogram indicating the analyzed sample groups on x-axis and the signals detected on y-axis. B, QRT-PCR analysis of pro-
tocadherin-24 mRNA expression in CaCo2 cells treated with FH535 and 5-ASA. Results are presented as bar histogram indicating the compound
concentrations on x-axis and the expression variations (relative quantity) of on y-axis. Asterisks indicate statistical significance. NCM, normal co-
lorectal mucosa; CRA, colorectal adenoma; CRC, colorectal carcinoma; IBD, inflammatory bowel diseases.
301Expression of protocadherins in CRCDako) was used at 1:200 dilution, and rabbit polyclonal antihu-
man μ-protocadherin and protocadherin-24 antibodies (Sigma-
Aldrich, Milan, Italy) were used at dilution 1:100. Positive con-
trols for both protocadherins were represented by proximal tu-
bules of the kidney and enterocytes of small and large
intestines. Therefore, we used the normal intestinal mucosa ad-
jacent to the tumor present in each analyzed case as a positive
internal control, and we considered the lymphoid tissuenormally present in the lamina propria as an internal negative
control. The presence of immune-reactive neoplastic cells
stained for μ-protocadherin and protocadherin-24 was graded
as follows: 0, negative (absence of membranous staining in all
neoplastic cells or b10%), and positive in more than 10% of
neoplastic cells. According to previous reports, expression of
β-catenin and E-cadherin in normal colon epithelium was re-
stricted to cell membrane. Altered expression of β-catenin
302 L. Losi et al.was contemplated when 10% of tumor cells or greater showed
nuclear or cytoplasmic immunoreactivity [17]. Loss of mem-
branous expression of E-cadherin was considered in cases
exhibiting either no immunoreactivity or 10% of tumor cells
or less with positive membranous staining. Detection of prolif-
erative activity was carried out using an anti–Ki-67 antibody,
and basal cells of the normal colonic crypts were used as an in-
ternal positive control. Ki-67 labeling index was determined
by counting the number of positive nuclei for 1000 tumor cells
in 10 consecutive fields chosen randomly in nonnecrotic areas
of the tumor. Statistical analysis of immunohistochemical data
was performed using the χ2 test and the Student t test.
2.3. DNA microarray analysis
Microarray analysis of protocadherin-24 messenger RNA
(mRNA) expression was carried out, as already described for
μ-protocadherin [6], using 2 distinct publicly available dataFig. 2 Expression of μ-protocadherin (A, original magnification ×100) a
protocadherins, the intensity of staining increases from the bottom to the top
and D, The same staining performed on transversally sectioned crypts (both
presented on the left and on the right.sets downloaded from Gene Expression Omnibus: the first,
provided by Galamb et al [18], contained 8 normal colorectal
mucosa (NCM) samples, 15 colorectal adenomas (CRAs), 15
CRCs, and 15 cases of inflammatory bowel diseases, and the
second, provided by Sabates-Bellver et al [19], contained 32
NCM samples and 32 CRCs. mRNA expression was assessed
as signal and indicated as the mean ± SEM values.
2.4. Cell cultures and treatment
TheCaCo2CRC cell line was obtained fromATCC (Rock-
ville, MD) and cultured as already described [9]. FH535
(Sigma-Aldrich) and 5-ASA (SofarFarm, Milan, Italy) were
respectively dissolved in dimethyl sulfoxide and complete me-
dium, added to cell cultures at the final concentrations, and
were incubated for 96 hours, as indicated in Results and in
the figures. Control cells were exposed to an equivalent
amount of vehicle. All the experiments were repeated at leastnd protocadherin-24 (B, ×100) in normal colorectal mucosa. For both
of the crypts and from the lateral to the apical borders of enterocytes. C
×400); μ-protocadherin and protocadherin-24 are again, respectively,
Table Results of immunohistochemical analysis performed in sporadic CRC and HNPCC cases
CRC
cases
Protocadherin expression n (%) β-c expression
(n)
Ki-67 positivity (%)
Mb Nc Mb β-c Nc β-c Global
Sporadic
(70)
μ-protocadherin + 26 (37) 19 7 46 68 52
− 44 (63) 1 43 60 68 68
Protocadherin-24 + 23 (33) 16 7 50 61 53
− 47 (67) 4 43 46 69 67
HNPCC
(15)
μ-protocadherin + 11 (71) 9 2 39 65 44
− 4 (29) 2 2 55 70 62
Protocadherin-24 + 10 (67) 8 2 41 65 45
− 5 (33) 3 2 47 70 56
NOTE. Expression of Ki-67 is reported as percentage of positive cells calculated in CRC cases exhibiting Mb β-c, Nc β-c, or both (global).
Abbreviations: +, positive immunohistochemical staining; − negative immunohistochemical staining; n, absolute number of cases; β-c, β-catenin; Mb, mem-
branous staining of β-catenin; Nc, nuclear staining of β-catenin.
303Expression of protocadherins in CRC3 times, and statistical analysis was performed using the
Student t test.
2.5. RNA extraction and quantitative real-time poly-
merase chain reaction
Total RNA was extracted with the Qiagen total RNA puri-
fication kit (Qiagen, Valencia, CA) and quantified using a
NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific,
Waltham, MA). cDNA synthesis was performed using 100 ng
of RNA for each sample with the High Capacity cDNA Retro-
transcription Kit (Invitrogen, Milan, Italy). Quantitative real-
time polymerase chain reaction (QRT-PCR) was then con-
ducted using an ABI PRISM 7900 detection system (Applied
Biosystems,Milan, Italy) [20]. All primers and probes used for
mRNA amplification were designed by Applied Biosystems.
Each cDNA sample was run in triplicate using the Taqman
Universal PCR Master Mix (Invitrogen), and GAPDH was
used as an endogenous control. Quantification of RT-PCR sig-
nals was performed using the Ct relative quantificationmethod
as described [21]. Statistical analysis was accomplished with
the Student t test.3. Results
3.1. DNA microarray analysis of protocadherin-24
mRNA expression in NCM and colorectal tumors
To provide a preliminary assessment of protocadherin-24
mRNA expression in colorectal tumors, we analyzed the mi-
croarray profiles of a number of NCM samples and CRA,
CRC, and inflammatory bowel disease cases contained in 2
distinct publicly available data sets downloaded from Gene
Expression Omnibus (see Materials and methods for more de-
tails). The results of this analysis showed an about 2-fold re-
duction of signal detected in CRA (P b .001) and CRC (P b
.05) as compared with NCM (Fig. 1A), disclosing anexpression pattern closely reminding that obtained for μ-
protocadherin under the same experimental conditions [6].
3.2. QRT-PCR analysis of protocadherin-24 mRNA
expression in FH535– and 5-ASA–treated CaCo2 cells
To evaluate the capacity ofβ-catenin inhibitors tomodulate
protocadherin-24 mRNA expression, we performed a QRT-
PCR analysis in CaCo2 cells upon a 96-hour incubation with
FH535 or 5-ASA. As shown in Fig. 1B, both treatments deter-
mined a strong increase of the analyzed parameter, appearing
more evident at the highest concentrations of the 2 compounds
and revealing an approximately 13-fold and 15-fold up-regula-
tion, respectively, with FH535 and 5-ASA (P b .05). Again,
protocadherin-24 mRNA exhibited a pattern of expression
very similar to that of μ-protocadherin, suggesting the exis-
tence of a biological correlation between the 2 considered pro-
tocadherins that we planned to better characterize in the
subsequent investigation.3.3. Immunohistochemical evaluation of
μ-protocadherin and protocadherin-24 expression
in sporadic CRC and HNPCC
The purpose of our study was to perform a comparative as-
sessment of μ-protocadherin and protocadherin-24 expression
that was conducted by immunohistochemical analysis on 70
sporadic CRCs and 15 HNPCCs with known germ-line muta-
tions affecting the MMR genes [14-16]. To gain additional in-
formation, the same evaluation was also extended to other
antigens such as β-catenin to determine its subcellular locali-
zation, Ki-67 to estimate the proliferation levels of tumor sam-
ples, and E-cadherin as a control.
The analysis of NCM put in evidence that the physiological
pattern of protocadherin-24 expression was virtually identical
to that of μ-protocadherin (Fig. 2). In fact, for both these 2 pro-











ig. 4 Pie charts representing the percentage of CRC cases charac-
rized by the loss of μ-protocadherin and/or protocadherin-24 ex-
ression in sporadic and HNPCC tumors.
Fig. 3 Representative cases of CRCwith expression ofμ-protocad-
herin (A, original magnification ×200) and absence of its expression
(B, ×100). The lower part of panel B contains an area of normal co-
lonic mucosa that, as expected, is positive for μ-protocadherin stain-
ing. Representative cases of CRC with expression of protocadherin-
24 (C, ×100) and absence of its expression (D, ×100). Membranous
expression of β-catenin in a CRC case (E, ×200) and nuclear expres-
sion of the same protein detected in a distinct CRC sample (F, ×200).
304 L. Losi et al.and the apical extrusion zone of enterocytes. In addition, its in-
tensity remarkably increased from the former to the latter site
of the cells and from the bottom to the top of the crypts. In this
regard, it is worth to underline that all the analyzed samples ofF
te
pNCM included in our study exhibited this expression pattern
both for μ-protocadherin and for protocadherin-24.
Interestingly, 63% of sporadic CRCs and only 29% of
HNPCCs exhibited a loss of μ-protocadherin expression, and
similarly, protocadherin-24 was not expressed in 67% of spo-
radic CRCs and in 33% of HNPCCs (Table). Representative
cases of positive and negative staining for μ-protocadherin
and protocadherin-24 are shown in Fig. 3A–D.3.4. Immunohistochemical evaluation of β-catenin,
Ki-67, and other antigens in sporadic CRC and HNPCC
Assessment ofβ-catenin was especially focused on the cor-
relation between its subcellular localization and the expression
pattern of the 2 investigated protocadherins. In this regard,
among sporadic CRCs, virtually all cases lacking μ-
protocadherin expression (43/44) and most cases lacking
protocadherin-24 expression (43/47) exhibited a nuclear
staining of β-catenin (Table). Consistently, in the same set of
patients, a membranous positivity of β-catenin was observed
in 19 of 26 cases maintaining μ-protocadherin expression
and 16 of 23 expressing protocadherin-24. Evaluation of
HNPCCs disclosed a similar trend in cases expressing the 2
protocadherins, whereas cellular β-catenin seemed equally
distributed between the membrane and the nucleus in cases
lacking their expression (Table). Fig. 3 also shows examples
of CRC with membranous or nuclear localization of β-
catenin (Fig. 3E and F).
Fig. 5 Bar histogram representing the percentages of CRC cases characterized by the loss of μ-protocadherin and/or protocadherin-24 expression in sporadic (light gray) and HNPCC (dark gray)
tumors. Reported values were calculated on the total number of CRCs, respectively, belonging to the 2 considered sample sets (sporadic and HNPCC). Asterisks indicate statistically significant







Fig. 6 Bar histogram representing the extent of Ki-67 expression (A, cell percentage) and β-catenin nuclear localization (B, case percentage) in CRC cases belonging to the various phenotype




307Expression of protocadherins in CRCEvaluation of Ki-67 positivity was measured as mean per-
centage and related to the expression pattern of the 2 protocad-
herins and to the subcellular distribution of β-catenin. No
substantial differences emerged in this analysis by the compar-
ison between sporadic CRC and HNPCC, and considering the
2 sets of patients all together, Ki-67 positivity averaged 67% in
μ-protocadherin–negative tumors and 51% in those positive
for its expression. Superimposable results were obtained for
protocadherin-24 where the same value was 66% in negative
cases and 51% in positive cases.
Loss of E-cadherin expression was detected in only 4 of the
70 analyzed sporadic CRC cases, all characterized by a normal
expression of μ-protocadherin and protocadherin-24, com-
bined with a location ofβ-catenin on the plasmatic membrane.
Conversely, none of the analyzed HNPCC cases exhibited an
absence of E-cadherin signal (not shown).
Based on the strict association, observed in sporadic CRC,
between the loss ofMLH1 expression and the onset of neoplasia
in the proximal colon, all cases of our study exhibiting that loca-
tion were also subjected to an immunohistochemical assessment
of MLH1 protein. The data obtained by this subset of patients
demonstrated that only 1 among a global number of 16 analyzed
samples showed a complete loss of MLH1 expression.
3.5. Numerical/statistical elaboration and
interpretation of data derived by
immunohistochemical analysis
A relevant finding arose by the evaluation of how the 2 pro-
tocadherins were distributed and reciprocally combined in the
various examined CRC cases. This approach, in fact, put in ev-
idence that double-negative cases (lacking expression of both
protocadherins) were 53% in sporadic CRC and only 13% in
HNPCC (Fig. 4). Consistently, double-positive cases (express-
ing both protocadherins) resulted in 14% and 54%, respec-
tively (Fig. 4). Both of these comparisons were statistically
significant with P values of less than .05 (Fig. 5). No substan-
tial differences were instead noted for single μ-protocadherin–
negative cases (10% in sporadic CRC versus 13% of HNPCC)
and single protocadherin-24–negative cases (23% in sporadic
CRC versus 20% of HNPCC).
Interestingly, within the subset of sporadic CRC patients
characterized by a location of the neoplasia in the proximal co-
lon (globally 16), 5 cases maintained the expression of both
protocadherins, and among them, 1 was MLH1 negative, indi-
cating that probably loss of MLH1 protein was not the only
factor promoting this phenotype.
Mean values of the Ki-67 labeling index seemed similar in
all the mentioned CRC case comparisons (Fig. 6A). Despite
this, double-negative CRCs exhibited higher percentages of
Ki-67 expression as compared with double-positive CRCs
(69% versus 48%,P b .05), with single negative/positive cases
placed in an intermediate situation.
Distribution of nuclear β-catenin positivity in the same
CRC categories showed, in general, a good correlation with
the expression pattern of Ki-67 (Fig. 6B). Not surprisingly,in HNPCC, β-catenin localized less frequently in the nuclear
compartment of cancer cells, in agreement with the more lim-
ited involvement of its pathway that has been demonstrated in
such tumors.
3.6. Correlation among immunohistochemical data
and clinical features of CRC patients
Evaluation of the histopathologic parameters revealed a sta-
tistically significant relationship between immunohistochemi-
cal data and histologic grade. In fact, high-grade tumors (poor
differentiated carcinomas) showed a more pronounced loss of
protocadherin expression as compared with low-grade tumors
(well and moderately differentiated; P b .05). A correlation
was also found between the loss of protocadherin expression
and the clinical stage because an increasing number of such
cases were observed in the transition from stages I to IV, al-
though this observation was not statistically significant. Simi-
larly, we detected a correlation between the presence of
metastasis after surgery and the absence of protocadherin ex-
pression, but without statistical significance (not shown).
4. Discussion
The purpose of this study was to assess whether expression
of μ-protocadherin and protocadherin-24 is down-regulated in
CRCs, focusing especially our attention on the distinction be-
tween sporadic CRC and HNPCC. The results obtained dis-
closed a significant discrepancy between the 2 sets of patients,
characterized by a more pronounced loss of protocadherin ex-
pression in the former than in the latter. In particular, the most
relevant finding of our analysis was represented by the observa-
tion that the percentage of double-negative cases lacking ex-
pression of both protocadherins seemed to be 4 times higher
in sporadic CRC than in HNPCC, whereas double-positive
cases expressing both protocadherins exhibited an opposite
trend. In both situations, CRC cases exhibiting a consensual ex-
pression of the 2 protocadherins (double negative and double
positive) largely prevailed on those characterized by expression
of a single protocadherin (single negative or single positive).
These data suggest the existence of a coordinated regulation in
the molecular control of μ-protocadherin and protocadherin-
24, which was also supported by our preliminary data of molec-
ular analysis presented in the initial part of the Results section.
Not surprisingly, in both patient groups, loss of protocadherin
expression was accompanied by a more frequent localization
of β-catenin in the nuclear compartment and an increased pos-
itivity of the Ki-67 proliferation marker. This observation
could be conceivably ascribed to the ability of protocadherins
to sequester β-catenin on plasmatic membrane, hampering its
nuclear translocation, as previously suggested by Parenti et al
[8] and Ose et al [12]. The lower frequency of protocadherin
down-regulation observed in HNPCC is in perfect agreement
with their best clinical outcome and with the different carcino-
genic mechanisms operating in these tumors, related to the
308 L. Losi et al.impairment of MMR genes rather than the constitutive activa-
tion of the β-catenin pathway, more typical of sporadic CRCs.
A recent report developed using a high-throughput approach
aimed to realize a systematic view of CRC somatic mutations
allowed for the identification of 2 subclasses of CRCs that
were respectively defined by authors as hyper and nonhyper-
mutated [22,23]. The hypermutated tumors (16% of all CRCs)
presented a high microsatellite instability, generally due to
promoter hypermethylation of the MLH1 gene and only in a
25% of cases to its somatic mutations. Both hypermutated
and nonhypermutated groups exhibited a deregulation in the
Wnt signaling pathway in apparent contrast with the data pre-
sented here. This divergence could, in our opinion, depend on
the fact that the mentioned study did not consider hereditary
CRC such as HNPCC. In addition, those that have been ana-
lyzed in our report harbor germ-line mutations of MMR genes
that affected not only theMLH1 but also theMSH2 andMSH6
genes. The different genetic background of studied tumors
could therefore provide an explanation for the discrepancy un-
der discussion.
To conclude, our data demonstrate for the first time that ex-
pression of protocadherin-24 is down-regulated in CRC, mim-
icking the expression pattern already observed for μ-
protocadherin, with which it seems to be functionally related.
As a logical consequence, CRCs losing the expression of both
protocadherins undergo higher proliferation levels as com-
pared with those losing a single protocadherin or maintaining
their expression. This indicates that the evaluation of panels
of cadherins/protocadherins rather than single cadherins or
protocadherin could help to better define the biological and
clinical features of CRCs in the future. These data could con-
tribute to obtain a detailed molecular classification of CRC fa-
voring a more accurate diagnosis and helping to develop
therapeutic strategies based on patient stratification for preci-
sion medicine.
Although of minor relevance, our study also allowed us to
characterize the physiological expression pattern of
protocadherin-24 in colorectal mucosa that once again paral-
leled that of μ-protocadherin, suggesting a role as differentia-
tion marker for both of these adhesion molecules.Acknowledgment
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